BioCentury
ARTICLE | Finance

June 15 Quick Takes: RA makes $200M investment in Novavax; plus venture rounds for Shattuck, ImmVira, Glyscend and Shukun

June 16, 2020 2:02 AM UTC

RA Capital to fund Novavax
Novavax Inc. (NASDAQ:NVAX) said Monday it will raise $200 million through a private placement of 4.4 million shares at $45.57, its closing price on Friday, to RA Capital Management. The funds will support clinical development of COVID-19 vaccine NVX-CoV2373 as well as help Novavax progress flu vaccine NanoFlu to BLA submission. The company gained $5.50 (12%) to $51.07 Monday.

Crossover investors in $118M series B for Shattuck
Shattuck Labs Inc. raised $118 million in a series B round led by Redmile Group, with participation from new investors Janus Henderson Investors, Fidelity, EcoR1 Capital, Hatteras Venture Partners, Avidity Partners, Partner Fund Management, Emerson Collective and Piper Sandler, plus undisclosed existing investors. The company is developing therapies to treat cancer and autoimmune diseases using its Agonist Redirected Checkpoint (ARC) platform, which consolidates checkpoint blockade and TNF superfamily agonism into a single therapeutic...